Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025906 | 0.79 | OPRD1 (0.39) | PTGDR2POLBTSHR | |
| SCHEMBL10025893 | 0.77 | P2RX7 (0.38) | PTGDR2P2RX7POLBTSHR | |
| SCHEMBL10025908 | 0.77 | P2RX7 (0.36) | PTGDR2P2RX7POLBTSHR | |
| SCHEMBL10025904 | 0.76 | MAPK1 (0.47) | — | |
| SCHEMBL13822113 | 0.75 | OPRD1 (0.38) | POLBTSHR | |
| SCHEMBL10025897 | 0.74 | P2RX7 (0.35) | PTGDR2P2RX7POLBTSHR | |
| SCHEMBL13822084 | 0.73 | DRD1 (0.47) | — | |
| SCHEMBL13809007 | 0.72 | GRIN2C (0.43) | P2RX7POLBTSHR | |
| SCHEMBL10025892 | 0.72 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL13809005 | 0.71 | KIF11 (0.50) | POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009073534-A2 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | APRT, PPA1, GNPAT | PTGDR2 2092/4885P2RX7 1334/4885POLB 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.